Phase III Technical Audit: Scaling to $N=125$

1. Executive Strategy: The "Efficiency Peak"
   We are transitioning from a $N=42$ pilot to a $N=125$ Industrial Standard. This move is a strategic shift to mathematically "lock in" the established Treatment 2 advantage against biological noise.

   1.1 The Statistical GoalCurrent State ($N=42$): Located in the "Gamble Zone." Probability of a False Negative (Type II Error) is 57%.Target State ($N=125$): Crossing the 80% Power Threshold. This minimizes the "Error Cost"—the financial risk of scaling an unvalidated treatment.

   1.2 Implementation Roadmap
   Step A: Variance Stabilization: Maintain the Robust-t ($M_3$) likelihood. As $N$ grows, the model must guard against "Late-Stage Outliers" (e.g., sensor failures      in the $N=80$ to $N=120$ range).
   Step B: Data Drift Monitoring: Run a Cumulative Posterior Update every 20 samples. The 95% High-Density Interval (HDI) must narrow significantly and remain            strictly above the 0.0 baseline.
   Step C: Efficiency Audit: Pay the "Robustness Tax" (MCMC compute time) to secure the 86% Reliability Gain.

2. Core Achievements: Validating "Outlier Efficacy"
   Increasing to $N=125$ achieves three critical engineering objectives:
   Outlier Dilution: In small samples, one "freak" plant can inflate the mean. At $N=125$, the mathematical weight of any single outlier is reduced by a factor of        $1/N$, forcing the model to rely on typical population behavior.
   Uncertainty Collapse: This makes our knowledge of growth 86% more stable. We move from a "likely range" to a fixed engineering constant.
   Robustness Stress-Test: We prove the $M_3$ model can maintain its 30.2% precision gain ($\sigma = 0.90$) even as biological variability increases in a larger          batch.

3. Phase III Monitoring Protocol
   3.1 Outlier Efficacy ThresholdsAction: Track the Normality Parameter ($\nu$). If $\nu < 10$, it confirms the presence of heavy-tailed biological outliers.
   Success Metric: If $M_3$ maintains $\sigma \approx 0.90$ despite these outliers, the precision gain is validated.
   The 95% HDI should narrow by 40–50% compared to the pilot.


   3.2 Statistical Stability Audit
$$\begin{array}{|l|l|l|}
\hline
\textbf{Variable} & \textbf{Verification Step} & \textbf{Industrial Target} \ \hline
\text{Posterior Mean } (\mu) & \text{Compare } N=125 \text{ to } N=42 \text{ (+0.49)} & \text{Deviation } < 10% \ \hline
\text{Noise Floor } (\sigma) & \text{Monitor for "Variance Creep"} & \text{Maintain } \sigma \leq 0.90 \ \hline
\text{Decision Stability} & \text{Calculate Reliability Gain at } N=125 & \text{Target } \approx 86% \text{ gain} \ \hline
\end{array}$$

3.3 Real-Time Intervention Triggers
TriggerIndicatorActionVariance Spike$\sigma > 1.10$$M_3$ is failing to suppress noise; audit sensor calibration.Certainty DropBayesian Certainty $< 95\%$Outlier efficacy is compromised; check for population shift.Convergence FailureHigh Autocorrelation / Low ESSIncrease MCMC thinning intervals for the larger dataset.

4. Final Verdict Requirement
   Upon reaching $N=125$, the final report must include this sign-off:
   STATUS: VALIDATED.
   Treatment 2 superiority is confirmed via $M_3$ architecture at $N=125$ with a finalized noise floor of $\sigma \leq 0.90$. The model is now cleared for industrial-scale deployment.

Technical Implementation Notes
The $\sigma$ Monitor: If $\sigma$ creeps toward the Gaussian $1.29$, your outlier mitigation is failing.
The Mean ($\mu$) Anchor: The +0.49 advantage is your "Ground Truth." If deviation exceeds 10%, the $N=42$ pilot was likely biased by sampling noise.
Reliability Gain: This is the ultimate metric justifying the extra sampling cost.



